There are no products in your shopping cart.
Pingclinicinc's Story Links
By Daniel Costello, Los Angeles Times Staff Writer
December 6, 2007
Genentech shares plunge. The vote could be a sign of tougher standards at the agency.
A Food and Drug Administration panel dealt a sharp blow to biotech giant Genentech Inc. on Wednesday by refusing to recommend approval for the company's high-profile drug Avastin as a treatment for breast cancer.
The news signaled to industry experts that federal regulators appear to be adopting stricter standards for drug approvals. It also sent the company's shares into free fall -- down more than 8% before trading was stopped in the afternoon.

YBM Life!







"The best of all healing worlds -- modern Western medicine blended with centuries-old Oriental wisdom."